1229337-32-9

Basic information

• Product Name: (1R,2S,5S)-3-((S)-2-(3-(1-(tert-butylsulfonylMethyl)cyclohexyl)ureido)-3,3-diMethylbutanoyl)-6,6-diMethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid
• Synonyms: (1R,2S,5S)-3-((S)-2-(3-(1-(tert-butylsulfonylMethyl)cyclohexyl)ureido)-3,3-diMethylbutanoyl)-6,6-diMethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid;Narlaprevir intermediate
• CAS NO: 1229337-32-9
• Molecular Formula: C₂₆H₄₅N₃O₆S
• Molecular Weight: 527.717
• Mol File: 1229337-32-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1R,2S,5S)-3-((S)-2-(3-(1-(tert-butylsulfonylMethyl)cyclohexyl)ureido)-3,3-diMethylbutanoyl)-6,6-diMethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2S,5S)-3-((S)-2-(3-(1-(tert-butylsulfonylMethyl)cyclohexyl)ureido)-3,3-diMethylbutanoyl)-6,6-diMethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid(1229337-32-9)
• EPA Substance Registry System: (1R,2S,5S)-3-((S)-2-(3-(1-(tert-butylsulfonylMethyl)cyclohexyl)ureido)-3,3-diMethylbutanoyl)-6,6-diMethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid(1229337-32-9)

Safety Data

• Hazardous Substances Data: 1229337-32-9(Hazardous Substances Data)

Usage

General Description

The chemical compound "(1R,2S,5S)-3-((S)-2-(3-(1-(tert-butylsulfonylMethyl)cyclohexyl)ureido)-3,3-diMethylbutanoyl)-6,6-diMethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid" is a complex molecule with a long name that describes its structure. It contains a cyclohexyl group, a ureido group, and a carboxylic acid group, among others, and is a derivative of azabicyclo[3.1.0]hexane. The compound has multiple chiral centers, indicating that it can exist in several different stereoisomeric forms. Its precise chemical and biological properties would depend on the specific stereochemistry and substituents attached to the molecule, and it may have potential applications in pharmaceuticals or chemical research.

Upstream product

• 1263416-49-4 C₁₈H₂₇NO₄S 
• 1263416-48-3 C₁₁H₂₃NO₂S 
• 1263416-47-2 C₁₅H₃₁NO₃S₂ 
• 1208245-85-5 C₁₈H₃₄N₂O₅S 
• 40195-26-4 1-methoxy-1-trimethylsilyloxymethylenecyclohexane 
• 848776-92-1 C₁₂H₂₁NO₃S 
• 848777-77-5 C₁₂H₂₂O₄S 
• 864185-89-7 C₁₂H₂₂O₂S 
• 864185-88-6 C₁₃H₂₄O₂S 
• 729559-16-4 N-cyclohexylidene-2-methylpropane-2-sulfinamide 
• 14094-12-3 tert-butyl methyl sulfone 
• 6163-64-0 tert-butyl methyl sulphide 
• 4630-82-4 methyl cyclohexylcarboxylate 
• 108-94-1 cyclohexanone 

Downstream Products

• 1227785-60-5 C₃₇H₆₃N₅O₇S 
• 865466-24-6 narlaprevir 
• 1256345-29-5 C₃₆H₆₃N₅O₇S 

Relevant articles and documents

ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF β-AMINO-α- HYDROXY AMIDES

Processes useful for the preparation of a Compound of Formula I: Formula (I). Intermediates useful for the preparation of the compound of Formula I, and processes useful for preparing said intermediates are disclosed.

Discovery of narlaprevir (SCH 900518): A potent, second generation HCV NS3 serine protease inhibitor

Boceprevir (SCH 503034), 1, a novel HCV NS3 serine protease inhibitor discovered in our laboratories, is currently undergoing phase III clinical trials. Detailed investigations toward a second generation protease inhibitor culminated in the discovery of narlaprevir (SCH 900518), 37, with improved potency (～10-fold over 1), pharmacokinetic profile and physicochemical characteristics, currently in phase II human trials. Exploration of synthetic sequence for preparation of 37 resulted in a route that required no silica gel purification for the entire synthesis.